Ozempic is a prescription medication made by Novo Nordisk and primarily used to treat patients with type 2 diabetes.

Wegovy is only approved for obesity in India. Novo Nordisk has no immediate plans to launch Ozempic for type 2 diabetes, ...

Novo Nordisk has launched Wegovy, a weight loss injection, in India, challenging Eli Lilly's Mounjaro. Available by June 2025 ...

Novo Nordisk has launched Wegovy in India, a weight-loss drug challenging Eli Lilly's Mounjaro. Available by June 2025, ...

CHMP recommends approval of Novo Nordisk’s Ozempic for peripheral arterial disease: Bagsværd, Denmark Wednesday, June 25, 2025, 15:00 Hrs [IST] Novo Nordisk, a leading global h ...

Novo Nordisk is banking on its pen-filled device and insulin leadership in India to gain a strong market share despite ...

The once-monthly drug is still under study but could provide added convenience and another option for patients.

Investing.com -- Novo Nordisk A/S (NYSE: NVO) stock dropped 2.1% premarket following news that Spain’s health ministry has requested clarification about the company’s obesity awareness campaign, which ...

If the drug is more broadly used in people with obesity and not just diabetes, those with higher body weights may see even ...

Mumbai: Novo Nordisk, a global healthcare company headquartered in Denmark, has announced the launch of Wegovy (injectable ...

NICE says that in some exceptional circumstances the BMI requirements can drop down to 30, and people from some ethnic ...

Wegovy, which is a prescription medicine is indicated to help manage weight and lower the risk of serious heart-related ...